Cardio Diagnostics Holdings, Inc. (CDIO) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Chicago, IL, United States. The current CEO is Meeshanthini V. Dogan.
CDIO has IPO date of 2022-01-14, 13 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $3.56M.
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
